Hysteroscopic view of endometrial hyperplasia

To determine the hysteroscopic appearance of endometrial hyperplasia in women with subsequently confirmed diagnosis of endometrial hyperplasia. This study was done in Aria Hospital in Ahwaz,Iran fromJanuary 21, 2003 to May 24th 2005. Fifty women underwent hysteroscopy with eye direct biopsy of the endometrium. Cause of hysteroscopy was Abnormal Uterine Bleeding [AUB] in 93.5% of cases. Specimens were sent for histology assessment. From these patients five cases had pathologic diagnosis of endometrial hyperplasia. Hysteroscopic features of these five cases were reviewed. In case one which was simple cystic hyperplasia, there was obvious cystic bizarre view. In case two, three and four there were minimal hysteroscopic abnormal view. In case 5 which was endometrial hyperplasia with atypia, there were obvious white endometrial elevations in the endometrial lining. Endometrial hyperplasia may produce obvious space occupying lesions in which diagnosis is easy with hysteroscopy, but it may be not very obvious especially in early stages of the disease. In all these 5 cases there were white areas with markedly reduced or absent vascularity

Comparison of effectiveness of two different premarin dose in hot flash treatment

Hot flush is the most common and severe problem of menopausal period. Estrogen is used for elimination of hot flush as an original and selective medicine. The objective was to determine the lowest useful dose because of estrogen's side effects. This clinical trial was done on 180 menopausal women who were complaining of hot flush. They were randomly divided in three groups. Group one took 0.3mg conjugated estrogen plus 1.25mg medroxyprogestronacetate, group two took 0.15mg conjugated estrogen plus 1.25mg medroxyprogestronacetate and group three took placebo for one month. Hot flush improvements in these three groups were defined. The average improvement was 78.5% with median 80 and mode 80 in group one [0.3 mg]. The average improvement was 63.3 percent with median 60 and mode 60 in group two [0.15mg]. The average improvement was 13.8% with median one and mode one in group three [placebo]. Due to average improvement of 63.3% in 0.15mg conjugated estrogen user group it is logical to begin hot flush treatment with this 0.15mg conjugated estrogen dose